661 Retatrutide monotherapy matches the effectiveness of anti-PD-1 immunotherapy in a preclinical model of pancreatic cancer
Marathe SJ, Bohm MS, Powell Z, et al. (2025). Journal for ImmunoTherapy of Cancer (SITC 2025 abstract supplement).
Summary
A conference abstract. Mice with diet-induced obesity were implanted with pancreatic cancer cells and randomised to vehicle, a low dose of retatrutide chosen not to cause weight loss, an anti-PD-1 antibody, or both, for two weeks. Retatrutide alone reduced tumour volume about three-fold versus vehicle, similar to anti-PD-1 alone (about five-fold); the combination gave no additional benefit. Body weight was stable across groups while blood glucose fell with retatrutide, which the authors take to mean the effect was independent of weight loss. Mechanism not established; abstract only, not a full peer-reviewed paper.